Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Viking reported a net loss of $158.3 million for Q1 2026, driven by increased R&D spend of $150.2 million as Phase 3 trials ramped up, though the company maintains a strong cash position of $603 million. The lead obesity program VK2735 reached significant milestones, with Phase 3 VANQUISH-1 and VANQUISH-2 trials now fully enrolled, and plans advancing to initiate Phase 3 trials for the oral formulation in 4Q26.
Key figures
- Guidance
- VK2735 maintenance dosing data expected 3Q26; Phase 3 oral VK2735 initiation expected 4Q26; Phase 1 VK3019 initiation expected 2Q26
- Net loss usd
- 158300000
- Rd expenses usd
- 150200000
- Cash position usd
- 603000000
- Vanquish 1 enrollment
- more than 4,500 patients
- Vanquish 2 enrollment
- approximately 1,000 patients
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.